International immunopharmacology
-
Int. Immunopharmacol. · Oct 2018
MicroRNA-146a protects against LPS-induced organ damage by inhibiting Notch1 in macrophage.
MicroRNA-146a is a well-studied microRNA participating in immune and inflammatory diseases, but its role in sepsis has not been investigated. Here in our study, we found increased level of microRNA-146a in macrophage stimulated by lipopolysaccharide. In addition, the mRNA level of Notch1 was also increased. ⋯ Knockout of Notch1 in macrophage showed reduced secretion of inflammatory factors and attenuated activation of NF-κB signaling in response to lipopolysaccharide. Specifically knockout of Notch1 in macrophage protected mice from LPS induced organ damage and dysfunction. Therefore, we prove that miR-146a acts as an inhibitor of inflammation by targeting Notch1 in macrophage, therefore protects mice from organ damage in sepsis.
-
Int. Immunopharmacol. · Oct 2018
Review Meta AnalysisImmune-related adverse events from combination immunotherapy in cancer patients: A comprehensive meta-analysis of randomized controlled trials.
Although available evidence from clinical trials has shown that immune checkpoint inhibitors (ICIs) combination therapy can lead to a series of immune-related adverse events (irAEs), the overall risk of irAEs on combination therapy has yet not been systematically reported. Therefore, we performed a meta-analysis to comprehensively explore the overall risks for irAEs on combination immunotherapy. ⋯ Patients receiving combination immunotherapy are at increased risk of selected all-grade irAEs. Although fatal high-grade irAEs is rare, AEs caused by combination immunotherapy should be recognized promptly in order to avoid more serious complications.
-
Int. Immunopharmacol. · Oct 2018
Transcriptomic analysis of lung tissues after hUC-MSCs and FTY720 treatment of lipopolysaccharide-induced acute lung injury in mouse models.
Acute lung injury and acute respiratory distress syndrome (ALI/ARDS) refer to acute and progressive hypoxic respiratory failure caused by non-cardiogenic factors, which is a common condition occurring in critically ill patients with widespread pulmonary inflammation. Use of a single medication or target cannot treat ALI/ARDS. Mesenchymal stem cells (MSCs) and FTY720, as an analogue of sphingosine-1-phosphate (S1P), can mitigate lipopolysaccharide (LPS)-induced inflammatory lung injury. ⋯ Transcriptomic analysis was performed using an Agilent gene expression chip. By analyzing the differences in gene expression of lung tissues between treated and non-treated ALI/ARDS mice, Gene Ontology and Pathway terms related to ALI/ARDS treatment were identified. Moreover, the target genes which might play a pivotal role in the treatment of ALI/ARDS were also detected, thus providing a theoretical basis for multi-target or multi-drug combined treatment of ALI/ARDS and lay a solid foundation for clinical treatment of ALI/ARDS.